Acquisition History / Novartis AG / Tourmaline Bio, Inc.
Novartis AG Acquires Tourmaline Bio, Inc.
Announced September 9, 2025 — $1.40B
What happened
Tourmaline Bio is a late-stage clinical biotechnology company developing medicines for inflammatory and immune diseases. It entered a merger agreement on September 9, 2025 under which Novartis will acquire it for $48.00 per share in cash, a total equity value of about $1.4B.
- Acquirer
- Novartis AG
- Target
- Tourmaline Bio, Inc.
- Announced
- September 9, 2025
- Price
- $1.40B
- Industry
- Inflammatory and immune disease biotechnology
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did Novartis AG acquire Tourmaline Bio, Inc.?
Novartis AG acquired Tourmaline Bio, Inc. on September 9, 2025. This was Novartis AG's 1st publicly tracked acquisition out of 1 we have on record.
How much did Novartis AG pay for Tourmaline Bio, Inc.?
Novartis AG paid $1.40B for Tourmaline Bio, Inc..
What does Tourmaline Bio, Inc. do?
Tourmaline Bio is a late-stage clinical biotechnology company developing medicines for inflammatory and immune diseases. It entered a merger agreement on September 9, 2025 under which Novartis will acquire it for $48.00 per share in cash, a total equity value of about $1.4B.
What other Inflammatory and immune disease biotechnology companies has Novartis AG acquired?
Tourmaline Bio, Inc. is Novartis AG's only publicly tracked acquisition in Inflammatory and immune disease biotechnology so far.